Sub-analysis of the Phase 2b CONTROL study in congenital ichthyosis demonstrates treatment success with TMB-001 regardless of subtype BASKING RIDGE, NJ, March 25, 2022 (GLOBE NEWSWIRE) -- via NewMediaWire --Timber Pharmaceuticals, Inc. ("Timber" or the “Company”) (NYSE American: TMBR), a biopharmaceutical company focused on the development and commercialization of treatments… Read More..

Topline data from Phase 2a trial of tegoprubart in ALS expected in 2Q 2022 Ongoing clinical studies evaluating tegoprubart in kidney transplantation, IgA nephropathy, and islet cell transplantation with initial readouts anticipated in late 2022 Cash balance of $84.8M, sufficient to fund operations into 2024 Conference call today at 4:30… Read More..

TORONTO, Ontario and CAMBRIDGE, MA , March 24, 2022 (GLOBE NEWSWIRE) -- ProMIS Neurosciences, Inc. (TSX: PMN) (OTCQB: ARFXF), a biotechnology company focused on the discovery and development of therapeutics targeting misfolded proteins such as toxic oligomers implicated in the development of neurodegenerative diseases, announced today that it will be… Read More..